Moreover, Aβ-PET Centiloids (CL) thresholds that can optimally predict functional decline have not yet been established. Methods Cross-sectional and longitudinal analyses over a mean three-year timeframe were performed on the European amyloid-PET imaging AMYPAD-PNHS dataset that phenotypes 1260 ...
E. et al. Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology 95, e1538–e1553 (2020). CAS PubMed PubMed Central Google Scholar Ossenkoppele, R. et al. Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. Neurology ...
The recent approval of [F]florbetapir by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in April and January 2013, respectively, for PET imaging of cerebral amyloid underlines the achievement of an important goal of molecular imaging, and emphasizes the potential ...
et al. Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J. Neurol. Neurosurg. Psychiatry 83, 923–926 (2012). Article PubMed PubMed Central Google Scholar Clark, C. M. et al. Cerebral PET with florbetapir compared with...
In the current study, vascular risk factors were collected for more than 25 years in participants from the Atherosclerosis Risk in Communities (ARIC) Study, with brain amyloid positron emission tomography (PET) imaging obtained in late life, to evaluate the associations among vascular risk factors,...
et al. Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J. Neurol. Neurosurg. Psychiatry 83, 923–926 (2012). Article PubMed PubMed Central Google Scholar Clark, C. M. et al. Cerebral PET with florbetapir compared with...
Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, Schwaiger M, Kurz A: Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003, 30: 1104-1113. 10.100...
(FDG) PET and atrophy on structural MRI as measures of neurodegeneration. Dynamic biomarker analysis revealed a prototypical sequence of biomarker changes in the pathogenic process [65,71]. Earliest changes appeared in CSF Aβ42, closely followed by amyloid PET imaging with an important lag period...
TDP-43 protein was recombinantly expressed as a fusion protein with a TEV cleavage site and an N-terminal hexa-histidine-tag in Escherichia coli BL21(DE3) pLysS cells that were transformed with the vector pET24-TDP-43. The protein was purified via nickel affinity chromatography as described pre...
Although AβOs do not interfere with the binding of NRX1β to NLG1 or LRRTM2, time-lapse imaging revealed that AβO treatment reduces surface expression of NRX1β on axons and that this reduction depends on the NRX1β HRD. In transgenic mice expressing mutated human amyloid precursor ...